21:12 , Feb 22, 2018 |  BC Innovations  |  Finance

Bigger BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is preparing to push projects in three areas past the pilot phase with $169 million in new NIH grants announced in 4Q17. The aim is to...
19:51 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million on Oct. 6 in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177, is...
19:53 , Oct 9, 2017 |  BC Extra  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177, is an oral recombinant...
19:11 , May 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting the calcium channel L-type could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a calcium channel L-type inhibitor decreased MS symptom scores, sensomotor...
22:46 , Feb 8, 2017 |  BC Week In Review  |  Clinical News

Elobixibat regulatory update

Eisai’s EA Pharma Co. Ltd. subsidiary submitted an NDA in Japan for elobixibat to treat chronic constipation. EA has exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA...
23:08 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; pancreatic cancer Patient sample and mouse studies suggest inhibiting CACNA1D or CACNA1S could help treat invasive breast and pancreatic cancers. In patients with invasive breast cancer, levels of CACNA1D were higher in tumors...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Elobixibat: Phase III data

Top-line data from a double-blind, Japanese Phase III trial in patients with chronic constipation showed that elobixibat for 14 days met the primary endpoint of improving the number of weekly SBMs from baseline to week...
07:00 , Oct 3, 2016 |  BC Extra  |  Clinical News

Albireo's elobixibat meets in Japanese Phase III study

Albireo AB (Gothenburg, Sweden) said elobixibat (AJG533/ A3309) met the primary endpoint in a Japanese Phase III study to treat chronic constipation. Compared with placebo, elobixibat significantly improved the number of weekly spontaneous bowel movements...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Elobixibat: Phase III started

Ajinomoto began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate once-daily oral elobixibat for 2 weeks in about 120 patients. Ajinomoto has exclusive rights from Albireo to elobixibat in Japan, South Korea, Thailand, Indonesia,...
07:00 , Apr 2, 2015 |  BC Innovations  |  Targets & Mechanisms

Breathing through bone drugs

Reversing or halting progressive airway damage is still the biggest challenge in COPD, but a study from Japan suggests a subclass of osteoporosis drugs could offer a new way to tackle the disease that takes...